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Treatment of Recent-Onset Type 1
Diabetic Patients With DiaPep277:
Results of a Double-Blind, Placebo-
Controlled, Randomized Phase 3
Trial
OBJECTIVE
To evaluate safety and efﬁcacy of DiaPep277 in preservingb-cell function in type 1
diabetic patients.
RESEARCH DESIGN AND METHODS
DIA-AID 1 is a multinational, phase 3, balanced-randomized, double-blind,
placebo-controlled, parallel-group clinical study. Newly diagnosed patients (N = 457,
aged 16–45 years) were randomized to subcutaneous injections of DiaPep277 or
placebo quarterly for 2 years. The primary efﬁcacy end point was the change from
baseline in the area under the glucagon-stimulated C-peptide curve. Secondary end
points were the change from baseline in mixed-meal stimulated C-peptide secre-
tion and in fasting C-peptide and achieving target HbA1c £7% (£53 mmol/mol).
Partial remission (target HbA1c on insulin £0.5 units/kg/day) and hypoglycemic
event rate were exploratory end points.
RESULTS
DiaPep277 was safe and well tolerated. Signiﬁcant preservation of C-peptide se-
cretion was observed in the DiaPep277-treated group compared with the placebo
(relative treatment effects of 23.4%, P = 0.037, and 29.2%, P = 0.011, in the
modiﬁed intent-to-treat [mITT] and per-protocol [PP] populations, respectively).
Themixed-meal stimulation failed to distinguish between the groups. There was a
trend toward efﬁcacy in fasting C-peptide levels, though not statistically signiﬁ-
cant. Signiﬁcantly more DiaPep277-treated than placebo-treated patients main-
tained target HbA1c (mITT 56% versus 44%, P = 0.03; PP 60% versus 45%, P =
0.0082) and entered partial remission (mITT 38% versus 29%, P = 0.08; PP 42%
versus 30%, P = 0.035). DiaPep277 treatment reduced the relative hypoglycemic
event risk (mITT by 20%; PP by 28%).
CONCLUSIONS
DiaPep277 safely contributes to preservation of b-cell function and to improved
glycemic control in patients with type 1 diabetes.
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Type 1 diabetes is caused by
autoimmune destruction of pancreatic
b-cells (1,2), resulting in severe decline
in endogenous insulin secretion.
Intensive insulin therapy reduces, but
does not eliminate, the risks of
complications from type 1 diabetes (3,4)
and normal glycemic control is difﬁcult
to achieve long term (5). Thus
considerable research effort is invested
in the search for safe and effective
means of downregulating the
autoimmune destruction of b-cells to
preserve residual function (6). Although
some successful phase 2 studies of
antigen speciﬁc and nonspeciﬁc
immune therapeutic agents have been
reported (7–13), there have been no
reports of positive results in phase 3
studies (14–16). Just recently, two
independent phase 2 trials failed to
demonstrate the efﬁcacy of interleukin-
1b inhibition as a means to halt
deterioration of b-cell function after the
onset of type 1 diabetes (17).
Consequently, no treatment modality
for the preservation of b-cell function
currently exists.
DiaPep277 is a 24 amino-acid peptide
derived from human heat-shock protein
60 that has been demonstrated to
modulate immunological attack on
b-cells in the NOD mouse model of
type 1 diabetes (18,19). The peptide
induces anti-inﬂammatory T-cells and
blocks destruction of b-cells while
preserving insulin secretion (20,21), as
was also demonstrated in a series of
phase 2 studies (22–24). Additional
studies demonstrated that DiaPep277
also activates regulatory T-cells by
interactingwith their Toll-like receptor 2
(25,26). Induction of regulatory T-cells
diverts the immune response toward
preservation of b-cells, rather than their
destruction, without affecting general
T-cell function in mice (27) and humans
(22,28), thus enabling a speciﬁc
treatment for type 1 diabetes without
suppressing essential immunological
functions.
The present DIA-AID 1 study was
designed to evaluate the safety and
efﬁcacy of DiaPep277 in preserving
endogenous production of insulin (as
indicated by C-peptide secretion) in
newly diagnosed type 1 diabetic adult
patients who also receive insulin.
RESEARCH DESIGN AND METHODS
Study Design
The full trial protocol (protocol version
6, Supplementary Data) and consent
documents were approved by
independent ethics committees of the
health authorities in each participating
country. All patients provided written
informed consent. DIA-AID 1 is a phase
3, multinational, balanced-randomized,
double-blind, placebo-controlled,
parallel-group study (Fig. 1 and
Supplementary Fig. 1). Patients were
males or females aged 16–45 years
(inclusive) who had recently been
diagnosed with type 1 diabetes (up to 4
months prior to recruitment). Major
inclusion criteria were patients were on
insulin treatment since diagnosis, had
fasting C-peptide levels of$0.22 nmol/L,
tested positive for the presence of at
least one of the diabetes-related
autoantibodies (IA-2 protein tyrosine
phosphatase, glutamic acid
decarboxylase, or insulin antibody), and
had a BMI of 17–28 kg/m2 (inclusive).
Major exclusion criteria were pregnancy,
signiﬁcant diseases that could affect
response to treatment, the presence of a
known clinically signiﬁcant immune
deﬁciency, or treatment with
immunosuppressive or cytotoxic drugs.
The sample size calculation for the
primary efﬁcacy end point was based on
meta-analysis of all phase 2 clinical trials
in newly diagnosed type 1 diabetic
patients in which the glucagon
stimulation test (GST) was the only
method used for evaluating the
C-peptide response (23,24). A sample size
of 126 in each group would have 90%
power to detect a signiﬁcant difference
between placebo and DiaPep277-
treated groups. Assuming that up to 15%
of patients might be lost to follow-up, in
order to ensure an adequate safety
database, the study was planned to
randomize up to 500 patients (250 per
treatment group).
Patients were screened (N = 679) and
then randomized (N = 457) throughout
the period of September 2005 to May
2009 in 46 outpatient centers in Europe
(Austria, Czech Republic, Finland,
France, Germany, Greece, Italy, Spain,
and England), Israel, and the Republic of
South Africa. Eligibility for enrolment in
the study was determined during the
screening phase (for parameters of
patients screened for eligibility, see
Supplementary Table 1). Study baseline
values were obtained and the baseline
mixed-meal tolerance test (MMTT) was
conducted after randomization at the
baseline visit when treatment was ﬁrst
administered (i.e., month 0). The
baseline GST was conducted 1 month
later, at month 1. Month 3 represented
the baseline value for glycemic
parameters data to allow time for newly
diagnosed patients to be stabilized.
Study Procedures
A full description of the study procedures
can be found in protocol version 6
(Supplementary Data). Brieﬂy, patients
were allocated randomly to receive drug
or placebo subcutaneously at months 0, 1,
3, 6, 9, 12, 15, 18, and 21 of the study.
Participants in the drug arm received
DiaPep277 (1 mg) with mannitol (40 mg)
in a 0.5mL lipid emulsion,while patients in
the placebo arm received only mannitol
(40 mg) in a 0.5 mL lipid emulsion. The
total study duration was 25 months,
including screening, treatment, and
follow-up (see Supplementary Fig. 1).
Participant randomization was
performed by an independent third
party, Almac Clinical Technologies
(Craigavon, U.K.), which randomly
assigned each patient a number linked
to one of the treatment arms and to a
medication kit. This company also
managed the assignment of participants
at all sites via a controlled interactive
voice/Web response system to
maintain a treatment randomization
ratio of 1:1 (DiaPep277:placebo) at each
study site and across the trial as a whole.
Randomization was stratiﬁed by basal
fasting C-peptide concentrations
(C-peptide $0.22 nmol/L or C-peptide
$0.40 nmol/L) and HbA1c ($7% [$53
mmol/mol] or ,7% [,53 mmol/mol]),
resulting in a total of four independently
randomized pretreatment strata.
Participants, investigator site staff,
persons performing the assessments,
and data analysts were blinded to
patient allocation from the time of
randomization until database lock.
Outcome Measures
Safety and tolerability assessments
were performed on the intent-to-treat
(ITT) population. These included
care.diabetesjournals.org Raz and Associates 1393
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assessment of adverse events (AEs),
serious AEs and treatment-emergent
adverse events (TEAEs), as classiﬁed
by theMedical Dictionary for Regulatory
Activities; clinical laboratory test
results; vital sign measurements;
electrocardiography; physical
examination; dermal hypersensitivity;
and hypoglycemic event rate.
Efﬁcacy analyses were performed on the
modiﬁed ITT (mITT) and per-protocol
(PP) populations. C-peptide was used
as a marker of insulin secretion and thus
of residual b-cell function (29). For the
primary efﬁcacy end point, patients
were evaluated if they had the area
under the glucagon-stimulated
C-peptide curve (AUC0–20) for baseline
and at least one efﬁcacy end point
evaluation post baseline. The
prespeciﬁed study populations were
deﬁned as follows: ITT, all randomized
patients who received at least one dose
of study medication; mITT, all ITT
patients who entered the study without
violation of major inclusion and
exclusion criteria; and PP, all mITT
patients who participated in the study
without signiﬁcant deviation in
compliance from the study protocol.
At the time of study initiation (2005)
there was no published guidance
regarding the preferred method for
C-peptide stimulation. The evaluation of
DiaPep277 efﬁcacy in all the phase 2
studies was based on GST, which is a
valid and commonly used procedure.
Consequently, the sample size
calculation for the phase 3 study was
based on the variance of the GST
procedure. Despite this, the MMTT was
selected as the primary method of
C-peptide stimulation because of its
growing popularity with experts and the
supposition that eventually it will
become the preferred method in
intervention studies.
While the DIA-AID 1 study was still
blinded and ongoing, the results of a
phase 2 study in DiaPep277-treated
latent autoimmune diabetes of adult
onset (LADA) patients that used both the
GST and MMTT methods of stimulation
were reported. To our surprise, the
results of this study showed clear and
unexpected differences between the
changes in C-peptide when measured by
MMTT versus GST [described in detail by
Pozzilli et al. (30)].
These differences and the fact that the
sample size of the DIA-AID 1 study was
calculated based on the glucagon
stimulation results from the phase 2
Figure 1—Flow diagram of the study. Patients recruited at 46 outpatient centers in 11 countries were screened (679), randomized (457), and
assigned to either the placebo or treatment. The mITT consisted of 422 patients after excluding 34 patients who were erroneously randomized in
violation of major inclusion/exclusion criteria. Missing data resulted in a further 73 patients being excluded from analysis for the primary end point.
Severe protocol violations occurred in 19 patients, who were excluded in the PP analysis. Incl/excl, inclusion/exclusion.
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studies prompted our Clinical Advisory
Board to recommend changing the
method of measurement of the primary
end point.
Accordingly, the change frombaseline in
the area under the 20-min GST-
stimulated C-peptide secretion curve
(AUC0–20) was redeﬁned as the primary
efﬁcacy outcome measure. The change
from baseline in the area under the 120-
min MMTT-stimulated curve (AUC0–120)
was retained as a secondary outcome
measure.
The study protocol was amended, and
the statistical analysis plan was planned
and ﬁnalized before the study was
unblinded, with the GST clearly deﬁned
as the primary end point.
This is the ﬁrst large trial in which long-
term changes in stimulated C-peptide
secretion levels were followed using
both measurement methods.
Additional secondary measures were
the percentage of patients
maintaining a treat-to-target HbA1c
level of #7% (#53 mmol/mol) at study
end and the difference in b-cell function
between the DiaPep277 and the
placebo groups, as determined by the
change in fasting C-peptide levels from
baseline to 24 months. Exploratory
clinical end points included the
proportion of patients who achieved
partial remission, deﬁned as HbA1c#7%
(#53 mmol/mol), with insulin doses of
#0.5 units/kg/day at study end, and the
number and rate of hypoglycemic
events during the study.
All laboratory tests were performed in
central laboratories. All samples,
including urine, hematology, blood
chemistry, C-peptide, and HbA1c, were
processed at LKF GmbH, Schwentinental,
Germany.
Two tests were used to measure
C-peptide secretion: the intravenous GST
and the 2-h MMTT. b-Cell function was
assessed by measurements of basal
fasting C-peptide at each visit,
intravenous glucagon-stimulated
C-peptide secretion at baseline (month 1)
and months 12 and 24, and MMTT-
stimulated C-peptide secretion at
baseline (month 0) andmonths 6, 12, 18,
and 24. Basal fasting and stimulated
C-peptide measurements were
performed in the morning after an
overnight fasting period of 8 to 10 h. The
tests were performed only if the fasting
glucose was in the range of 4 to 11.1
mmol/L (72 to 200 mg/dL). Investigators
were blinded to the GST and MMTT
results in order to maintain the blind to
study treatment.
Glucagon (GlucaGen HypoKit, Novo
Nordisk), 1 mg, was administered
intravenously at time “0” within 15 s.
Blood samples for the determination of
C-peptide were drawn at –5 min before
and immediately before glucagon
administration (time 0) and at 2, 6, 10,
and 20 min postadministration (65 min).
The standard MMTT consisted of the
oral ingestion of a standardized liquid
mixed meal (Ensure, Abbott; calculated
for each patient as 6mL/kg bodyweight,
up to 360 mL). Blood samples for the
determination of C-peptide were drawn
at 210 min before and immediately
before the liquid meal ingestion (time 0)
and at 10, 20, 30, 60, 90, and 120 min
(65 min) postingestion.
C-Peptide was measured using
radioimmunoassay kit (Human
C-peptide RIA kit, LINCO). The analytical
range of the assay is 0.0331–1.655
nmol/L.
Autoantibodies associated with type 1
diabetes were tested at the Diabetes
Research Center of the Free University
of Brussels, Belgium, under the
supervision of Dr. Patrick Goubert and
Prof. Frans Gorus.
Data Analysis
All statistical methods complied with
Guidance for Industry: E9 Statistical
Principles for Clinical Trials (31).
Analyses were performed using SAS
version 9.2 or above for Windows.
Outcomes are reported for two
populations: an mITT group and a PP
group. The mITT group was created [in
line with Fergusson et al. (32)] after data
lock and before study unblinding to
correct for the mistaken randomization
of 34 ineligible patients into the trial
(Fig. 1 and Supplementary Table 2). The
PP population consisted of all mITT
patients who did not signiﬁcantly
deviate from the study protocol.
The mixed-effects model for repeated
measurements (MMRM) was used as
the ﬁrst statisticalmethod for analysis of
efﬁcacy and was applied to all the
patients in both the mITT and the PP
groups. Every participant for whom
there existed at least one postbaseline
measurement was included in the
MMRM analysis, with the model
imputing the missing data points
(33,34). TheMMRMwas used to analyze
the change from baseline in the primary
and secondary end points using SAS
PROC MIXED. The model included ﬁxed
effects for baseline fasting C-peptide
and categorical model terms for
treatment group, visit number, and
country. A variance components matrix
was used to model the covariance
structure. P values were obtained from
differences of least square means at
each visit. A P value of ,0.05 was
considered signiﬁcant.
Relative treatment effect was deﬁned as
the ratio between the changes in area
under the curve (AUC) in the DiaPep277-
treated group compared with the
placebo group. The hypoglycemic
events data were analyzed using paired t
tests to compare the value for each
patient at baseline (month 3) with the
value at 24 months. For detailed
calculations, see Supplementary Data.
For hypoglycemia classiﬁcations see
Supplementary Table 3.
Interim Analysis
An interim analysis intended for sample
size re-estimation was performed when
approximately 100 patients reached
24 months. No stopping rules were set
up for early termination and no type I
error adjustment was carried out. All the
type I errors will be spent in the ﬁnal
analysis. An interim analysis data safety
monitoring board (IA-DSMB) was
appointed to review the results of the
interim analysis. The unblinded outputs
of the interim analysis were not
accessed by any person other than the
members of the IA-DSMB.
The IA-DSMB conclusions and
recommendations following the interim
analysis were to continue the study as
planned.
RESULTS
Two hundred twenty-two patients
screened were not eligible for the trial,
mainly because they lacked
autoantibodies (24.3%) or had low
care.diabetesjournals.org Raz and Associates 1395
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C-peptide levels (24.3%) (Fig. 1 and
Supplementary Table 4). The treatment
and placebo arms were comparable in
terms of demographic data, medical
history data, and baselinemetabolic and
b-cell function parameters (Table 1).
The higher male preponderance (66%
males, 34% females) was mainly
because female participants were
required to use a birth control method
throughout the 2-year study duration.
Three hundred forty-nine patients from
the mITT population and 330 patients
from the PP population were evaluable
for the primary efﬁcacy end point (i.e.,
data were available at baseline and at
least one time point postbaseline)
(Fig. 1).
One hundred two patients (22%) did not
complete the study, 50 from the
DiaPep277-treated arm and 52 from the
placebo-treated arm. The main reasons
were withdrawal of consent (7.8%), loss
to follow-up (4%), noncompliance with
study requirements (2%), and AE (2%).
Withdrawal for any reason was
balanced between the two treatment
arms (see Supplementary Table 5).
Noncompleters who had at least one
time point postbaseline were evaluable




C-peptide secretion levels than did
placebo-treated patients at the end of
the study, month 24. Signiﬁcantly less
decline in AUC0–20 from baseline to
study endwas observed inmITT patients
who were treated with DiaPep277 as
compared with placebo-treated
patients (23.108 vs.24.058; difference
0.949 [95% CI 0.056–1.843] nmol/L/20
min; P = 0.037), which equates to a
relative treatment effect of 23.4% (Fig.
2A). A similar result was obtained in
the PP population (22.857 in the
DiaPep277-treated group vs. 24.037 in
the placebo-treated group; difference
1.180 [95% CI 0.271–2.088] nmol/L/20
min; P = 0.0011), a relative treatment
effect of 29.2% (Fig. 2B).
Unlike the results obtained in the GST-
stimulated C-peptide secretion, the
MMTT-stimulated C-peptide secretion
did not differ between the groups (Fig.
2C).
From the GST-stimulated C-peptide
concentration curve, the maximum
C-peptide concentration (Cmax) was
extracted. The change from baseline in
Cmax was consistent with the change in
C-peptide AUC0–20. In both the mITT
and PP populations, the DiaPep277-
treated group exhibited less decline in
Cmax than the placebo-treated group
(20.185 vs. 20.247, difference 0.062
[95% CI 0.005–0.118] nmol/L/20 min,
P = 0.032 for a relative treatment effect
of 25% in the mITT population and
20.166 vs. 20.246, difference 0.08
[95% CI 0.024–0.137] nmol/L/20 min,
P = 0.005 for a relative treatment effect
of 32% in the PP population)
(Supplementary Fig. 2).
A relative treatment effect of 20% was
obtained for the difference in fasting
C-peptide levels between the treatment
and placebo groups at study end.
Although not statistically signiﬁcant, it
supports the treatment effect obtained
by GST.
A signiﬁcantly higher proportion of
patients maintained HbA1c #7% (#53
mmol/mol) at study end in the
DiaPep277-treated group as compared
with the placebo group in both the mITT
population (56 and 44%, respectively;
P = 0.03) (Fig. 3A) and the PP population
(60 and 45%, respectively; P = 0.0082)
(Fig. 3B). As a result of the tight glycemic
control of patients that was required
throughout the study andmaintained by
administering maximal insulin to
prevent b-cell glucotoxicity, the mean
HbA1c levels of the groups at study end
were not expected to be signiﬁcantly
different: 27.32% (56 mmol/mol) and
7.11% (54 mmol/mol) in the DiaPep277-
treated group compared with 7.39% (57
mmol/mol) and 7.30% (56mmol/mol) in
the placebo group for the mITT and the
PP populations, respectively.
An exploratory analysis revealed that, in
both themITT and PP populations, there
was a higher proportion of patients in
partial remission at study end in the
DiaPep277-treated group than in the
placebo group. Speciﬁcally, in the mITT
population, 38.4% of patients achieved
partial remission compared with 29.3%
in the placebo population (P = 0.08). The
corresponding values for the PP
Table 1—Demographic and baseline parameters of randomized patients
Parameter DiaPep277 Placebo
Sex (male/female) 142/83 158/73
Age (years) 26.6 6 7.99 (15–46) 26.4 6 7.85 (15–46)
Time since diagnosis (months) 2.76 6 1.2 (0.77–7.6) 2.8 6 1.3 (0.5–7.4)
BMI (kg/m2) 22.87 6 3.0 (17–35.4) 23.02 6 3.1 (17–34.4)
Fasting C-peptide (nmol/L) 0.38 6 0.22 (0.03–1.62) 0.39 6 0.28 (0.05–3.4)
Baseline AUC0–20 by GST (nmol/L/20 min) 10.81 6 7.21 (1.39–78.01) 10.61 6 6.48 (1.05–49.53)
Baseline AUC0–120 by MMTT (nmol/L/120 min) 106.49 6 60.28 (19.8–620.3) 100.18 6 53.15 (12.25–398.5)
HbA1c (%) 7.27 6 1.65 (4–16.4) 7.50 6 1.70 (4.5–14.6)
HbA1c (mmol/mol) 56.0 6 18.0 (20–156) 58.4 6 18.9 (26–136)





Data are average 6 SD (range) unless otherwise speciﬁed. IA-2A, IA-2 protein tyrosine phosphatase; IA, insulin antibody; GADA, glutamic acid
decarboxylase.
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population were 41.8 and 30.2% (P =
0.035) for the treatment and placebo
groups, respectively (see
Supplementary Table 6).
There were fewer hypoglycemic events
per month in the mITT population in the
DiaPep277-treated group compared
with the placebo group (69 vs. 83,
respectively) as well as fewer
hypoglycemic events per month per
patient (0.57 vs. 0.71, respectively). The
same trends were observed in the PP
population (55 vs. 83 hypoglycemic
events per month and 0.51 vs. 0.71
hypoglycemic events per month per
patient for the treatment and placebo
groups, respectively). The decrease in
the rate of hypoglycemic events from
month 3 to study end in the DiaPep277-
treated group was signiﬁcant (20.18,
P = 0.012 for the mITT population and
20.26, P = 0.0004 for the PP population),
while there was no signiﬁcant change
in the placebo-treated group (20.04,
P = 0.644 for both the mITT and PP
populations) (Fig. 3C and D). Indeed,
treatment with DiaPep277 reduced the
overall relative risk of a patient suffering a
hypoglycemic episode over the 2 years of
the study by 20% in the mITT population
and by 28% in the PP population.
Safety
The most common AE considered
related to the study drug was
discomfort at the injection site upon
administration. No laboratory
abnormalities, changes in vital signs,
general immune system suppression,
increases in infections or autoimmune
diseases, or signiﬁcant differences in
serious AE or AE frequencies were
observed between treated and
untreated patients. In the DiaPep277-
treated group, three patients (1.3%)
experienced at least one serious TEAE
that was considered to be related to the
study drug, namely, diverticulitis,
erythema nodosum, and hypoglycemia.
In the placebo group, one patient (0.4%)
experienced at least one serious TEAE
that was considered to be related to the
study drug, namely, neutropenia.
Twenty-three patients (10.2%) in the
DiaPep277-treated group and 13
patients (5.6%) in the placebo group
experienced at least one serious TEAE
not considered to be drug related. All
TEAEs resolved completely (see
Supplementary Table 7).
There were three cases of serious
hypoglycemia in two subjects in each
the DiaPep277-treated and the placebo-
treated group. In the case of the
DiaPep277-treated subject who
suffered two incidences of serious
hypoglycemia, the investigator reported
them as drug related. There was one
case of hypoglycemic coma in each the
DiaPep277-treated and the placebo-
treated group considered not to be drug
related.
CONCLUSIONS
The current study shows that DiaPep277
has an excellent safety proﬁle, in line
with previous studies (22–24). Over 500
type 1 diabetic patients have been
exposed to DiaPep277 for up to 2 years
without safety concerns. Subjects
treated with DiaPep277 were not
immunocompromised and were spared
the side effects characteristic of
immunosuppressive drugs, which
suggests that DiaPep277 treatment
at 3-monthly intervals could be continued
as long as required. A recently completed
extension study showed that up to 4
years of continued treatment has not led
to any drug-related health concerns (35).
Additional studies will determine
whether and to what extent continued
treatment is needed to maintain long-
term treatment effect.
A most encouraging result of this study
is the improved clinical outcome related
to better glycemic control, as shown
by a signiﬁcant increase in the
proportion of patients maintaining the
target HbA1c level at study end in the
DiaPep277-treated group. It is
important to note that this was attained
without any increase in insulin dose, as
evidenced by the higher number of
patients in the DiaPep277-treated group
who achieved partial remission.
Moreover, the number of hypoglycemic
events per month in the DiaPep277-
treated group decreased over the
course of the study, in contrast to the
placebo-treated group, whose rate
remained unchanged. This improved
metabolic control in the DiaPep277-
treated group most likely resulted from
the preservation of a clinically
signiﬁcant degree of endogenous insulin
secretion, as evidenced by a smaller
decline in C-peptide AUC0–20 secretion
in response to glucagon stimulation.
Initially, the MMTT was selected as the
primary method for measuring efﬁcacy
and the GST as a secondary method.
During the course of the study, while it
was still blinded, it became apparent
that there might be discrepancies
between the twomethods (as explained
in detail in OUTCOME MEASURES). These
differences and the fact that the sample
size of the DIA-AID 1 study was
calculated based on the glucagon
stimulation results from the phase 2
Figure 2—Change from baseline (6SEM)
in the area under the C-peptide secretion
curve as determined using the 20-min GST
(AUC0–20) in (A) the mITT population and (B)
the PP population. (C) Change from baseline
(6SEM) in the area under the C-peptide
secretion curve as determined using the 120-
min mixed-meal stimulation test (AUC0–120)
in the mITT population. *P , 0.05.
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studies prompted us to redeﬁne the
primary end point as the change in
C-peptide AUC from baseline to study
end after stimulationwith glucagon. The
change in MMTT-stimulated C-peptide
was redeﬁned as a secondary end point.
While GST-stimulation showed that
DiaPep277 treatment yielded, in
addition to positive clinical outcomes,
preservation of b-cell function, the
MMTT-stimulation failed to detect a
difference between the two study
groups.
Correlation analyses indicated that
although the absolute values of
stimulated C-peptide measured by GST
and MMTT were reproducible and well
correlated when evaluated at each
individual time point, the changes in AUC
obtained by the two methods over the
course of the study were only weakly
correlated. Since the change in AUC over
time from baseline (rather than absolute
AUCs) indicate the dynamics of disease
progression, only this parameter should
be used to calculate treatment effect and
preservation of residual b-cell function in
intervention studies.
Additional analyses indicated that the
differences between the outcome
measures are statistically robust and
may reﬂect differences in the biological
response to the stimulations.
This inconsistency between the GST-
and MMTT-stimulated C-peptide results
has not been reported in other long-
term intervention trials, because no
other trials have evaluated patients by
both procedures. This is the ﬁrst long-
term intervention trial that uses both
procedures simultaneously and so
enables such an observation.
The discrepancy between the GST and
the MMTT results is described in detail
by Pozzilli et al. (30).
Figure 3—The percentage of patients achieving HbA1c #7% (53 mmol/mol) in (A) the mITT population and (B) the PP population. The average
number (6SEM) of hypoglycemic events per month in (C) the mITT population and (D) the PP population. The number of hypoglycemic events per
month at baseline was computed as the total number of events recorded up until month 3 divided by the number of months (3). Thereafter, this
value was computed as the total number of hypoglycemic events frommonth 3 until the date of the speciﬁed visit divided by the number of months,
on the basis of 30-day months. *P , 0.05.
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A second, conﬁrmatory phase 3 study
is ongoing using both methods of
stimulation. This will allow the collection
of a large amount of data that could
possibly aid in understanding the
discrepancy between the two methods.
The ability of DiaPep277 to arrest the
autoimmune destruction of b-cells at the
early nonsymptomatic state should also
be explored.
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